Sandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries

NovartisSandoz today announces the expansion of a pilot project with leading charity World Child Cancer, aimed at improving access to treatment and optimizing survival outcomes for children suffering from cancer in four developing countries. The agreement builds on an existing partnership with World Child Cancer in the Philippines, where Sandoz is funding staff training needs and helping children to access diagnosis and subsequent treatment. It expands the partnership to cover three additional countries across three continents: Ghana, Mexico and Myanmar.

These particular projects were chosen because of the gravity of the situation in the four regions concerned: across all four, an estimated 6000 children develop cancer each year, but only approximately 20% even receive a diagnosis, let alone effective treatment.

Jon Rosser, Chief Executive of World Child Cancer, said: "It is just unacceptable that children's odds of surviving cancer depend so much on geography. In developed countries, 80% now survive, but in developing countries it's still only about 10%. World Child Cancer is changing this - in our programs we can raise that survival rate to around 60%."

He added: "We are very excited at this growing partnership with Sandoz, which will enable us to prevent so many children dying without even a diagnosis and without effective pain relief. We believe that all children, regardless of where they live, deserve better."

Peter Stenico, Sandoz Head of Oncology, said: "These projects will take simple, pragmatic measures to attack cancer where it is most vulnerable: among children suffering from forms of cancer that are often absolutely treatable. Together with World Child Cancer, we believe we can make a real difference by enhancing the standard of care for children in these countries and, ultimately, improving childhood cancer survival rates."

The expanded partnership highlights Sandoz's commitment to work together with key stakeholders worldwide to expand access to healthcare. As a targeted philanthropy project, our work with World Child Cancer complements our broader Novartis Corporate Responsibility efforts across a number of lower income countries.

About Sandoz
Sandoz is a global leader in generic pharmaceuticals and biosimilars. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people's lives. We contribute to society's ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1000 molecules, covering all major therapeutic areas, accounted for 2016 sales of USD 10.1 billion. In 2016, our products reached well over 500 million patients and we aspire to reach one billion. Sandoz is headquartered in Holzkirchen, in Germany's Greater Munich area.

About World Child Cancer
World Child Cancer helps children with cancer access diagnosis, treatment and support in developing countries where the chances of survival can be as low as 10% compared with 80% in the developed world.

World Child Cancer does this by building partnerships between doctors and nurses at hospitals in the developed world who provide training and mentoring for doctors in developing countries. It also helps with transport, food and accommodation costs to meet the wider needs of families who have a child with cancer.

World Child Cancer programs run in some of the poorest places in the world. Last year it helped over 5,500 children but, with an estimated 200,000 unnecessary deaths each year, there is so much more that needs to be done.

Most Popular Now

Novo Nordisk announces plans to transform its appr…

Novo Nordisk announced plans to restructure its Research & Development (R&D) organisation to accelerate the expansion and diversification of its pipeline across serious c...

The Merck Accelerator Program 2019

The Merck Accelerator is looking for real partners so that you can work together in shaping the future. With programs in the headquarters in Germany, in China and the Sat...

World's largest Alzheimer's survey reveals most ad…

Amgen (NASDAQ:AMGN), Novartis and Banner Alzheimer's Institute (BAI), in association with Alzheimer's Disease International (ADI), announced results from the largest glob...

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Pre-clinical success for a universal flu vaccine o…

Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Co...

Discovery could explain failed clinical trials for…

Researchers at King's College London have discovered a vicious feedback loop underlying brain degeneration in Alzheimer's disease which may explain why so many drug trial...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

Aspirin found not to prolong healthy aging

Taking a low-dose aspirin daily does not prolong healthy living in older adults, according to findings from the ASPirin in Reducing Events in the Elderly (ASPREE) trial p...

The Lancet Respiratory Medicine publishes first Ph…

AstraZeneca today announced publication of results from the KRONOS Phase III trial which evaluated the efficacy and safety of triple combination therapy PT010 (budesonide...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

Clinical gene discovery program solves 30 medical …

A table in a recently published paper tells the story of 30 families who have, sometimes after years of searching, finally received an answer about the condition that has...